Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Provigil modafinil: Phase II; marketed to treat excessive daytime sleepiness associated with narcolepsy

CEPH presented additional data from its previously reported 72-patient U.S. Phase II

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE